Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cy-tokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcope-nia was defined with appendicular skeletal muscle mass over height2 (ASM/heigh2). Results: Over-all, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5–33.1 vs. 61 weeks, 95% CI 22.5–99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011). Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.

Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (Ncscl) treated with immune checkpoint inhibitors (icis): a prospective study / Tenuta, M.; Gelibter, A.; Pandozzi, C.; Sirgiovanni, G.; Campolo, F.; Venneri, M. A.; Caponnetto, S.; Cortesi, E.; Marchetti, P.; Isidori, A. M.; Sbardella, E.. - In: CANCERS. - ISSN 2072-6694. - 13:24(2021). [10.3390/cancers13246355]

Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (Ncscl) treated with immune checkpoint inhibitors (icis): a prospective study

Tenuta M.
Co-primo
;
Gelibter A.
Co-primo
;
Pandozzi C.;Sirgiovanni G.;Campolo F.;Venneri M. A.;Caponnetto S.;Cortesi E.;Marchetti P.;Isidori A. M.
Penultimo
;
Sbardella E.
Ultimo
2021

Abstract

Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cy-tokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcope-nia was defined with appendicular skeletal muscle mass over height2 (ASM/heigh2). Results: Over-all, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5–33.1 vs. 61 weeks, 95% CI 22.5–99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011). Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.
File allegati a questo prodotto
File Dimensione Formato  
Tenuta_Impact of sarcopenia_2021.pdf

accesso aperto

Note: https://www.mdpi.com/2072-6694/13/24/6355
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 843.58 kB
Formato Adobe PDF
843.58 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1599252
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact